Product Description: Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist. Resiquimod (GMP) can induce human mMDSC to mature into inflammatory macrophages[1][2][3].
Applications: COVID-19-immunoregulation
Formula: C17H22N4O2
References: [1]Bayik D, et al. Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages. Front Immunol. 2018 Mar 26;9:608. /[2]Preisendörfer S, et al. FK506-Binding Protein 11 Is a Novel Plasma Cell-Specific Antibody Folding Catalyst with Increased Expression in Idiopathic Pulmonary Fibrosis. Cells. 2022 Apr 14;11(8):1341. /[3]Lee M, et al. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014;37(9):1234-40.
CAS Number: 144875-48-9
Molecular Weight: 314.38
Research Area: Cancer; Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Toll-like Receptor (TLR)
English
Deutsch
